Drug–clay nanohybrids as sustained delivery systems
Source abstract
Abstract
Abstract Biocompatible 2-dimensional layered compounds such as clays and layered double hydroxides (anionic clays) have been explored and utilized in drug delivery system for therapeutic application because they can safely encapsulate drug molecules via intercalation reaction. Therefore, various kinds of drug molecules and bio-functional molecules with cationic or anionic charge have been incorporated into clay delivery carriers, giving rise to the heterostructured layered nanohybrids with chemo-therapeutic and gene-therapeutic functions. Recently, such inorganic delivery systems have received growing attention because their inertness and low toxicity gives rise to safety and stability in bio-systems. Furthermore, the hybridization of drug with clays offers the fascinating features such as controlled and sustained release, improved water-solubility, and even protective and targeted delivery. Unique release behaviors of drugs from the drug–clay nanohybrids are originated from molecular level incorporation, and strong interaction between drug and inorganic layers including electrostatic and hydrogen bonding interactions. In the present review, various drug–clay nanohybrids will be introduced, and their recent development will be highlighted in the viewpoint of oral administration drugs with controlled and sustained release.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Layered Double Hydroxides Synthesis and Applications · Clay minerals and soil interactions · Intestinal and Peritoneal Adhesions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Use of clays as drug delivery systems: possibilities and limitations10.1016/j.clay.2006.06.015 ↗
2. Chitosan–silicate biocomposites to be used in modified drug release of 5-aminosalicylic acid (5-ASA)10.1016/j.clay.2010.07.011 ↗
3. Synthesis and characterization of a novel pH-controllable composite hydrogel for anticancer drug delivery10.1039/c1nj20672a ↗
4. Toxicological effects of a cationic clay, montmorillonite in vitro and in vivo10.1007/s13273-012-0012-x ↗
5. Effect of orally administered glutathione-montmorillonite hybrid systems on tissue distribution10.1155/2012/469372 ↗
6. Montmorillonite intercalated with glutathione for antioxidant delivery: synthesis, characterization, and bioavailability evaluation10.1016/j.ijpharm.2012.01.015 ↗
7. 2013
8. Biopolymer–clay hydrogel composites as drug carrier: host–guest intercalation and in vitro release study of lidocaine hydrochloride10.1016/j.clay.2011.03.017 ↗
9. Layered double hydroxide-based nanocarriers for drug delivery10.3390/pharmaceutics6020298 ↗
10. Chapter 2. Structure and mineralogy of clay minerals
11. Montmorillonite nanodevices for the colon metronidazole delivery10.1016/j.ijpharm.2013.09.017 ↗
12. Modification of ibuprofen drug release from poly(ethylene glycol) layered silicate nanocomposites prepared by hot-melt extrusion10.1002/app.40284 ↗
13. Clay minerals and their beneficial effects upon human health. A review10.1016/S0169-1317(01)00085-0 ↗
14. Clay and non-clay minerals in the pharmaceutical industry10.1016/j.clay.2009.07.017 ↗
15. Clays, drugs and human health
16. Cervini-Silva · Colloids Surf. B: Biointerfaces · 2015 · 129 · 110.1016/j.colsurfb.2015.03.019 ↗
17. Crystal structure refinements of palygorskite and Maya Blue from molecular modelling and powder synchrotron diffraction10.1127/0935-1221/2003/0015-0021 ↗
18. Tramadol hydrochloride/montmorillonite composite: preparation and controlled drug release10.1016/j.clay.2010.04.011 ↗
19. Inorganic nanovehicle targets tumor in an orthotopic breast cancer model10.1038/srep04430 ↗
20. Human-related application and nanotoxicology of inorganic particles: complementary as pects10.1039/B711208D ↗
21. Inorganic metal hydroxide nanoparticles for targeted cellular uptake via clathrin-mediated endocytosis10.1002/asia.200800290 ↗
22. Intercalative route to heterostructured nanohybrid10.1016/j.jpcs.2003.10.047 ↗
23. Intercalative nanohybrids of nucleoside monophosphates and DNA in layered metal hydroxide10.1021/ja981823f ↗
24. Inorganic layered double hydroxide as a non-viral vector10.1002/1521-3773(20001117)39:22<4041::AID-ANIE4041>3.0.CO;2-C ↗
25. Choy · A hybrid of free-base amlodipine with a layered silicate and a process for preparing the same. PCT Int. Appl. WO · 2005 · 2005018679 · A1
26. Choy, J.H., Park, T., Lee, Y.J., Kim, D.Y., Park, J.K., 2008. A base forming drug-layered silicate hybrid containing basic polymer and its synthesis method. PCT Int. US 0119519 A.
27. Clay minerals and layered double hydroxides for novel biological applications10.1016/j.clay.2006.07.007 ↗
28. In vitro release of sodium diclofenac from poloxamer 188 modified montmorillonite as an oral drug delivery vehicle
29. Clay: new opportunities for tissue regeneration and biomaterial design10.1002/adma.201301034 ↗
30. Cell proliferation and controlled drug release studies of nanohybrids based on chitosan-g-lactic acid and montmorillonite10.1016/j.actbio.2008.08.007 ↗
31. Properties and applications of palygorskite–sepiolite clays10.1180/claymin.1996.031.4.01 ↗
32. Laponite clay as a carrier for in situ delivery of tetracycline10.1039/c3ra43217c ↗
33. Guggenheim, S, Krekeler, M. P.S., 2011. The structures and microtextures of the palygorskite–sepiolite group minerals. In: Galan E., Singer, A. (Ed.), Developments in Palygorskite-Sepiolite Research; A New Outlook on These Nanomaterials, Elsevier, Amsterdam, 299–324.10.1016/B978-0-444-53607-5.00001-3 ↗
34. Formulation and antibacterial profiles of clay–ciprofloxacin composites10.1016/j.clay.2013.10.020 ↗
35. Hybrid materials based on clays for environmental and biomedical applications10.1039/c0jm00432d ↗
36. Antibacterial kaolinite/urea/chlorhexidine nanocomposites: experiment and molecular modelling10.1016/j.apsusc.2014.04.008 ↗
37. IARC monographs on the evaluation of carcinogenic risks to humans
38. Montmorillonite–alginate nanocomposite as a drug delivery system – incorporation and in vitro release of irinotecan10.1016/j.ijpharm.2013.08.043 ↗
39. Naturally occurring clay, montmorillonite, as a drug delivery vehicle for in vitro extended release of venlafaxine hydrochloride
40. Pleural carcinogenic potency of mineral fibres (asbestos, attapulgite) and their cytotoxicity on cultured cells
41. Multiple renal silica calculi10.1136/bmj.1.5846.146 ↗
42. Design and evaluation of controlled drug delivery system of buspirone using inorganic layered clay mineral10.1016/j.micromeso.2010.04.003 ↗
43. Itraconazole-laponite: kinetics and mechanism of drug release10.1016/j.clay.2007.09.002 ↗
44. Synthesis and characterization of biodegradable clay–polymer nanocomposites for oral sustained release of anti-inflammatory drug
45. Diclofenac sodium adsorption onto montmorillonite: adsorption equilibrium studies and drug release kinetics10.1260/0263-6174.32.5.365 ↗
46. Layered bionanocomposites as carrier for procainamide10.1016/j.ijpharm.2010.01.002 ↗
47. Biopolymer–clay hydrogel composites as drug carrier: host–guest intercalation and in vitro release study of lidocaine hydrochloride10.1016/j.clay.2011.03.017 ↗
48. Layered inorganic nanocomposites: a promising carrier for 5-fluorouracil (5-FU)10.1016/j.ejpb.2012.01.004 ↗
49. Montmorillonite/poly-(epsilon-caprolactone) composites as versatile layered material: reservoirs for anticancer drug and controlled release property10.1016/j.ejps.2012.04.009 ↗
50. 2D inorganic-antimalaria drug–polymer hybrid with pH-responsive solubility10.1002/asia.201500347 ↗
51. Palygorskite polypyrrole nanocomposite: A new platform for electrically tunable drug delivery10.1016/j.clay.2014.06.020 ↗
52. Cell toxicity, haemolytic action and clastogenic activity of asbestos and its substitutes10.2486/indhealth.29.37 ↗
53. Carvedilol/montmorillonite: processing, characterization and release studies10.1016/j.clay.2010.03.008 ↗
54. A nanohybrid system for taste masking of sildenafil
55. Effect of bentonite on the physical properties and drug-release behavior of poly(AA-co-PEGMEA)bentonite nanocomposite hydrogels for mucoadhesive10.1002/app.13499 ↗
56. Pepsin hydrolysis of the adherent mucus barrier and subsequent gastric mucosal damage in the rat: effect of diosmectite and 16, 16 dimethyl prostaglandin E2
57. Silica stones in the urinary bladder10.1016/S0140-6736(82)92620-4 ↗
58. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier10.1016/S0142-9612(01)00325-8 ↗
59. Adsorption and photooxidation of pharmaceuticals and personal care products on clay minerals10.1007/s11144-011-0349-5 ↗
60. Compositional, technical and safety specifications of clays to be used as pharmaceutical and cosmetic products10.1016/j.clay.2006.06.016 ↗
61. Pharmaceutical and cosmetic uses of fibrous clays
62. Advantageous delivery of nifedipine from inorganic materials showing increased solubility and biocompatibility10.1016/j.micromeso.2013.09.021 ↗
63. Pharmaceutical properties of supramolecular assembly of co-loaded cardanol/triazole-halloysite systems10.1016/j.ijpharm.2014.12.004 ↗
64. Drug-induced urinary calculi
65. Increasing dissolution rates of poorly soluble drugs by adsorption to montmorillonite10.3109/03639048009051925 ↗
66. Sustained-release applications of montmorillonite interaction with amphetamine sulfate10.1002/jps.2600660115 ↗
67. Controlled release and antibacterial activity chlorhexidine acetate (CA) intercalated in montmorillonite10.1016/j.ijpharm.2009.08.004 ↗
68. Loading and delivery of sertraline using inorganic micro and mesoporous materials10.1016/j.ejpb.2006.11.023 ↗
69. Integrated bio-inorganic hybrid systems for nano-forensics10.1039/C0CS00051E ↗
70. Aripiprazole-montmorillonite: a new organic–inorganic nanohybrid material for biomedical applications10.1002/chem.201203384 ↗
71. The Maya blue nanostructured material concept applied to colouring geopolymers10.1039/C5RA14076E ↗
72. X-ray diffraction and X-ray absorption spectroscopic analyses for intercalative nanohybrids with low crystallinity
73. Polymer–inorganic supramolecular nanohybrids for red, white, green, and blue applications10.1016/j.progpolymsci.2013.05.007 ↗
74. Controlled release of donepezil intercalated in smectite clays10.1016/j.ijpharm.2008.04.012 ↗
75. Sustained release of venlafaxine from venlafaxine–montmorillonite–polyvinylpyrrolidone composites10.1016/j.clay.2010.11.013 ↗
76. Interactions of attapulgite (fibrous clay) with human red blood cells10.1016/0378-4274(89)90149-5 ↗
77. Intraperitoneal injection studies for the evaluation of the carcinogenicity of fibrous phyllosilicates
78. The crystal structure of talc10.1346/CCMN.1973.0210206 ↗
79. The systems containing clays and clay minerals from modified drug release: a review10.1016/j.colsurfb.2012.10.068 ↗
80. Drug-loaded polyurethane/Clay Nanocomposite Nanofibers for topical drug-delivery application10.1002/app.40230 ↗
81. Synthesis and characterization of chlorhexidine acetate drug–montmorillonite intercalates for antibacterial applications10.1016/j.clay.2014.09.010 ↗
82. Drug release behavior of polyurethane/clay nanocomposite: Film vs. nanofibrous web10.1002/app.40824 ↗
83. Polyoxypropylene-montmorillonite nanocomposites for drug-delivery vehicles: preparation and characterization10.1002/app.35609 ↗
84. In vitro biocompatibility and mucoadhesion of montmorillonite chitosan nanocomposite: a new drug delivery10.1016/j.clay.2011.11.006 ↗
85. Intestinal permeability of oxytetracycline from chitosan-montmorillonite nanocomposites10.1016/j.colsurfb.2013.11.009 ↗
86. IR and x-ray diffraction study of chlorpheniramine maleate-montmorillonite interaction10.1002/jps.2600691004 ↗
87. Physicochemical study of the interaction of montmorillonite with hydralazine hydrochloride, a cardiovascular drug10.1016/0169-1317(88)90005-1 ↗
88. Clay–polymer nanocomposites as a novel drug carrier: synthesis, characterization and controlled release study of propranolol hydrochloride10.1016/j.clay.2013.06.009 ↗
89. In vitro sustained delivery of atenolol, an antihypertensive drug using naturally occurring clay mineral montmorillonite as a carrier
90. Organoclay pluronic f68 – montmorillonite, as a sustained release drug release drug delivery vehicle for propranolol hydrochloride
91. Preparation of a novel PEG-clay hybrid as a DDS material: dispersion stability and sustained release profiles10.1016/j.jconrel.2005.03.031 ↗
92. Host-guest interaction between swelling clay minerals and poorly water-soluble drugs. 1. complex formation between a swelling clay mineral and griseofulvin10.1007/BF01066211 ↗
93. Halloysite clay nanotubes for resveratrol delivery to cancer cells10.1002/mabi.201200121 ↗
94. Current challenges in clay minerals for drug delivery10.1016/j.clay.2010.01.007 ↗
95. Pharmaceutical applications of some Spanish clays (sepiolite, palygorskite, bentonite)_some preformulation studies10.1016/S0169-1317(98)00050-7 ↗
96. Experimental studies with palygorskite dusts
97. Preparation and characterization of cefradine/montmorillonite composites10.4028/www.scientific.net/AMR.560-561.434 ↗
98. Recent advances in the synthesis and application of layered double hydroxide (LDH) nanosheets10.1021/cr200434v ↗
99. Biopolymer/montmorillonite nanocomposite: preparation, drug-controlled release property and cytotoxicity10.1088/0957-4484/19/6/065707 ↗
100. Clay Nanotube/Poly(methyl methacrylate) Bone Cement Composites with Sustained Antibiotic Release Macromol